Kyverna Therapeutics, Inc.'s KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients with Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

Kyverna Therapeutics, Inc. announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its autologous, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of stiff-person syndrome (SPS) in Kyverna's trial, named KYSA-8.